AQR Capital Management
AQST icon

AQR Capital Management’s Aquestive Therapeutics AQST Stock Holding History

AQR Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
51,594
-10,115
-16% -$41.1K ﹤0.01% 3571
2025
Q4 		$399K Buy
61,709
+3,934
+7% +$24.5K ﹤0.01% 3032
2025
Q3 		$323K Sell
57,775
-974
-2% -$4.21K ﹤0.01% 3053
2025
Q2 		$194K Sell
58,749
-70,270
-54% -$202K ﹤0.01% 3056
2025
Q1 		$374K Buy
129,019
+14,025
+12% +$42.5K ﹤0.01% 2583
2024
Q4 		$409K Sell
114,994
-15,806
-12% -$72.9K ﹤0.01% 2350
2024
Q3 		$651K Buy
+130,800
New +$509K ﹤0.01% 2059
2021
Q2 		– Sell
-19,786
Closed -$103K – 2219
2021
Q1 		$103K Hold
19,786
– – ﹤0.01% 2154
2020
Q4 		$106K Buy
19,786
+776
+4% +$4.65K ﹤0.01% 2150
2020
Q3 		$92K Buy
+19,010
New +$124K ﹤0.01% 2142

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management's AQST Position: Q1 2026 in Review

AQR Capital Management reduced its Aquestive Therapeutics (AQST) stake by 16% in Q1 2026, selling an estimated $41.1K and leaving 51,594 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #3571.

AQR Capital Management first reported a position in AQST in Q3 2020 and has held it in 10 quarters since. The position peaked at $651K in Q3 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • AQR Capital Management held 51,594 shares of Aquestive Therapeutics worth $214K as of Q1 2026.
  • AQR Capital Management sold 10,115 Aquestive Therapeutics shares in Q1 2026, an estimated $41.1K.
  • Aquestive Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3571 holding.
  • AQR Capital Management first reported a position in Aquestive Therapeutics in Q3 2020 and has held it in 10 quarters since.
  • AQR Capital Management's Aquestive Therapeutics position peaked at $651K in Q3 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.